These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35191235)

  • 1. Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification.
    Cho HW; Lee H; Ju HY; Yoo KH; Koo HH; Lim DH; Sung KW; Shin HJ; Suh YL; Lee JW
    J Korean Med Sci; 2022 Feb; 37(7):e59. PubMed ID: 35191235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
    Eid AM; Heabah NAE
    J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
    Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
    Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
    Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
    Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
    Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Classification of Medulloblastoma.
    Kijima N; Kanemura Y
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorship.
    Gupta T; Mani S; Chatterjee A; Dasgupta A; Epari S; Chinnaswamy G
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):589-598. PubMed ID: 38761170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subgroups of medulloblastoma: the current consensus.
    Taylor MD; Northcott PA; Korshunov A; Remke M; Cho YJ; Clifford SC; Eberhart CG; Parsons DW; Rutkowski S; Gajjar A; Ellison DW; Lichter P; Gilbertson RJ; Pomeroy SL; Kool M; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):465-72. PubMed ID: 22134537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
    Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
    J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile.
    Sadighi Z; Vats T; Khatua S
    J Child Neurol; 2012 Oct; 27(10):1302-7. PubMed ID: 22826514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
    Kim JW; Park SH; Choi SA; Kim SK; Koh EJ; Won JK; Nam SM; Phi JH
    BMC Cancer; 2022 Nov; 22(1):1221. PubMed ID: 36437460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
    Yeo KK; Margol AS; Kennedy RJ; Hung L; Robison NJ; Dhall G; Asgharzadeh S
    J Neurooncol; 2019 Nov; 145(2):375-383. PubMed ID: 31621042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
    da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
    J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.